Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. | Am J Cardiol;79(11): 1471-4, 1997 Jun 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.

Ochiai, M; Isshiki, T; Takeshita, S; Eto, K; Toyoizumi, H; Sato, T; Miyashita, H.

Affiliation

Ochiai M; The Second Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.

Am J Cardiol ; 79(11): 1471-4, 1997 Jun 01.

Article in En | MEDLINE | ID: mdl-9185635

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Tetrazoles / Coronary Thrombosis / Platelet Aggregation Inhibitors / Stents Type of study: Etiology_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Cardiol Year: 1997 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Tetrazoles / Coronary Thrombosis / Platelet Aggregation Inhibitors / Stents Type of study: Etiology_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Cardiol Year: 1997 Document type: Article Affiliation country: Country of publication: